APA

Brana I., Calles A., LoRusso P. M., Yee L. K., Puchalski T. A., Seetharam S., Zhong B., de Boer C. J., Tabernero J. & Calvo E. (20151209). Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. : Targeted oncology.

Chicago

Brana Irene, Calles Antonio, LoRusso Patricia M, Yee Lorrin K, Puchalski Thomas A, Seetharam Shobha, Zhong Bob, de Boer Carla J, Tabernero Josep and Calvo Emiliano. 20151209. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. : Targeted oncology.

Harvard

Brana I., Calles A., LoRusso P. M., Yee L. K., Puchalski T. A., Seetharam S., Zhong B., de Boer C. J., Tabernero J. and Calvo E. (20151209). Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. : Targeted oncology.

MLA

Brana Irene, Calles Antonio, LoRusso Patricia M, Yee Lorrin K, Puchalski Thomas A, Seetharam Shobha, Zhong Bob, de Boer Carla J, Tabernero Josep and Calvo Emiliano. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. : Targeted oncology. 20151209.